Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Tranzyme Pharama says its new treatment for diabetic gastroparesis, a disabling disorder in which the stomach takes too long to empty its contents, has shown positive results in phase II clinical trials among diabetic patients with the digestive disorder. The pharmaceutical company was granted “fast-track status” by the Food and Drug Administration (FDA) for TZP-102, a designation that is typically reserved for drugs that treat serious and unmet medical needs. The designation is designed to speed up the review and approval process.

Read the rest of this entry »

When 57-year-old August Macaluso, a former nuclear-plant maintenance worker in Charlotte, N.C., began shaking violently, blinking incessantly and slurring his speech, he and his wife Sharon were both puzzled. Desperate for answers, Sharon Googled his symptoms and learned that the drug her husband had been taking for just three months was linked to the involuntary movement disorder Tardive Dyskinesia with frighteningly similar symptoms. He stopped taking the drug and after a battery of medical tests, doctors confirmed the Macalusoes’ worst fears. August had suffered permanent damage.

Read the rest of this entry »

A new medical center specializing in gastrointestinal disorders is opening in El Paso, Texas, offering hope to patients throughout the country who suffer from debilitating symptoms. The new center is a collaborative effort between the University Medical Center of El Paso and Texas Tech University Health Sciences Center Paul L. Foster School of Medicine. Called the Center for Gastrointestinal Motility and Functional Bowel Disorders, the center will diagnose and treat people who have problems digesting food.

Read the rest of this entry »